Who are Savaysa's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Bevyxxa, Arixtra, Arixtra, Xarelto, FXIII Concentrate (Human), Fondaparinux - UFH indicated.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/edoxaban.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Savaysa — Competitive Intelligence Brief

Savaysa (edoxaban) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Factor Xa Inhibitor. Area: Cardiovascular.

marketed Factor Xa Inhibitor Coagulation factor X Cardiovascular Live · refreshed every 30 min

Target snapshot

Savaysa (edoxaban) — Daiichi Sankyo Inc. Savaysa works by blocking the action of coagulation factor X, a key protein involved in blood clotting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Savaysa TARGET	edoxaban	Daiichi Sankyo Inc	marketed	Factor Xa Inhibitor	Coagulation factor X	2015-01-01
Bevyxxa	BETRIXABAN	Portola Pharms Inc	marketed	Factor Xa Inhibitor	Coagulation factor X	2017-01-01
Arixtra	FONDAPARINUX	Mylan Ireland Ltd	marketed	Factor Xa Inhibitor	Coagulation factor X	2001-01-01
Arixtra	Arixtra	LifeBridge Health	marketed		Antithrombin-III, Coagulation factor X
Xarelto	Xarelto	University Hospital, Montpellier	marketed		Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X
FXIII Concentrate (Human)	FXIII Concentrate (Human)	CSL Behring	phase 3	Coagulation factor concentrate	Coagulation Factor XIII (F13A1)
Fondaparinux - UFH indicated	Fondaparinux - UFH indicated	GlaxoSmithKline	phase 3	Factor Xa inhibitor	Factor Xa (Coagulation Factor X, activated form)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Factor Xa Inhibitor class)

Daiichi Sankyo Inc · 1 drug in this class
Mylan Ireland Ltd · 1 drug in this class
Portola Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Savaysa — Competitive Intelligence Brief. https://druglandscape.com/ci/edoxaban. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab